Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph phase_3
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

recruiting2100%

Recent Activity

2 active trials
Showing 2 of 2
recruitingphase_3

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

NCT06675214
recruitingphase_3

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

NCT06092957

Clinical Trials (2)

Showing 2 of 2 trials
NCT06675214Phase 3

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

Recruiting
NCT06092957Phase 3

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
2